With respect to designing the most appropriate dominant negative PrP molecular approaches for prion disease therapy, it is known that genetic variation in the PRNP gene can influence susceptibility to prion disease in humans [20,25], while codon 171 variants in sheep and codon 163 variants in Canidae confer prion disease resistance in those mammals [26]. The gene discussed is PRNP; the disease is prion disease.